A Phase 3 interventional study of Lurasidone tablets and Risperidone tablets in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-15.
Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 10th largest by enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 29th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2013.
This study's enrollment of 388 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma (Suzhou) Co., Ltd., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma (Suzhou) Co., Ltd. is the lead sponsor of 13 studies on the registry; none are open to participants now.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2013, is one of 21 in phase 3, and was the 28th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lurasidone tablets
Drug: Risperidone tablets
Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
Also known as: LATUDA
Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores.
Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 6 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores\<70 is the normal,but the scores\>120 is more serious.
Time frame: From baseline to Week 6(day 42).
Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6.
The Clinical Global Impression Scale-Improvement (CGI-I) Score is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline state at the beginning of the intervention. Response is rated as one of the following, in which higher scores indicate less improvement or worsening: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse.
Time frame: From baseline to Week 6(day 42).
| Milestone | Lurasidone Group | Risperidone Group |
|---|---|---|
| Started | 194 | 194 |
| Completed | 166 | 168 |
| Not completed | 28 | 26 |
Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 6 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores\<70 is the normal,but the scores\>120 is more serious.
| units on a scale | Lurasidone Group | Risperidone Group |
|---|---|---|
| Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Scores. | -31.2 (-33.2 to -29.2) | -34.9 (-36.8 to -32.9) |
The Clinical Global Impression Scale-Improvement (CGI-I) Score is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline state at the beginning of the intervention. Response is rated as one of the following, in which higher scores indicate less improvement or worsening: 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very much worse.
| units on a scale | Lurasidone Group | Risperidone Group |
|---|---|---|
| Mean Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6. | 2.0 (1.9 to 2.1) | 1.9 (1.8 to 2.0) |
Collected over Date of first dose of study medication and up to 7 days after date of last dose of treatment in double-blind phase, an average of 7 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone Group | 0/194 (0%) | 1/194 (0.5%) | 134/194 (69.1%) |
| Risperidone Group | 0/191 (0%) | 0/191 (0%) | 160/191 (83.8%) |
| Event | Lurasidone Group | Risperidone Group |
|---|---|---|
| Hand fractureInjury, poisoning and procedural complications | 1/194 | 0/191 |
| Event | Lurasidone Group | Risperidone Group |
|---|---|---|
| Extrapyramidal disorderNervous system disorders | 33/194 | 73/191 |
| ConsitpationGastrointestinal disorders | 25/194 | 28/191 |
| NasopharyngitisInfections and infestations | 19/194 | 28/191 |
| Blood prolactin increasedInvestigations | 6/194 | 27/191 |
| AkathisiaNervous system disorders | 14/194 | 26/191 |
| InsomniaPsychiatric disorders | 19/194 | 19/191 |
| Upper respiratory tract infectionInfections and infestations | 10/194 | 16/191 |
| AnxietyPsychiatric disorders | 12/194 | 12/191 |
| Weight increasedInvestigations | 1/194 | 10/191 |
| DizzinessNervous system disorders | 5/194 | 8/191 |
Intent-to-treat population (ITT) : All randomized subjects who received at least one dose of study medication,were included in the Intent-to-treat population.
| Age, Categorical(Participants) | Lurasidone Group | Risperidone Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 194 | 190 | 384 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Lurasidone Group | Risperidone Group | Total |
|---|---|---|---|
| Mean | 34.6 ± 11.12 | 34.8 ± 10.71 | 34.7 ± 10.91 |
| Sex: Female, Male(Participants) | Lurasidone Group | Risperidone Group | Total |
|---|---|---|---|
| Female | 96 | 89 | 185 |
| Male | 98 | 101 | 199 |
| Region of Enrollment(participants) | Lurasidone Group | Risperidone Group | Total |
|---|---|---|---|
| China | 194 | 190 | 384 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2013, a primary completion of Apr 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma (Suzhou) Co., Ltd. →